Institute of Oncology Ljubljana — Biomedical Watch V2

Traitements4programmes

Essais2liés

Publications4liées

SourceDBlocale

Traitements

4

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
Assessment of Endocrine and Metabolic Late Effects After Childhood Brain Tumor TreatmentThis prospective, single-group interventional study evaluates endocrine and metabolic late effects in survivors of primary brain tumors treated during childhood. According to the study protocol, participants were prospectively assigned to undergo the Study-Specific Endocrine and Metabolic Late-Effects Assessment. The assessment included anthropometric measurements, repeated blood pressure measurements, clinical endocrine evaluation, fasting laboratory testing, and protocol-defined bone and vascular assessments. The purpose of the study was to identify the frequency and severity of endocrine and metabolic late effects and to evaluate their associations with tumor characteristics, previous cancer treatment, age at diagnosis, and physical functioning.	Cancer	Non applicable	À vérifier	Slovenia	À vérifier
ASTRA Study: Circulating Tumor Cells in Blood of Patients With High-Grade Serous Ovarian CancerHigh-grade serous ovarian cancer is typically diagnosed at an advanced stage and remains associated with poor long-term survival. Reliable biomarkers for predicting disease course and treatment response are still limited. Circulating tumor cells (CTCs) are malignant cells that detach from the primary tumor and enter the bloodstream. Their presence has been associated with disease progression and prognosis in several malignancies, including ovarian cancer. However, data on the morphological characteristics, immunophenotype, and clinical relevance of CTCs in high-grade serous ovarian cancer remain limited. The ASTRA study evaluates the number and characteristics of circulating tumor cells in peripheral blood samples obtained from patients with high-grade serous ovarian cancer. The study examines CTC count, presence of CTC clusters and megakaryocytes, and immunophenotypic marker expression, and explores associations between CTC findings and clinical parameters and outcomes. Results from this study may contribute to improved understanding of circulating tumor cells in ovarian cancer and support the development of liquid biopsy approaches for prognostic assessment and disease monitoring.	Cancer	NA	Ralentissement de la progression + Immunomodulation	Slovenia	À vérifier
ASTRA Study: Circulating Tumor Cells in Blood of Patients With High-Grade Serous Ovarian CancerHigh-grade serous ovarian cancer is typically diagnosed at an advanced stage and remains associated with poor long-term survival. Reliable biomarkers for predicting disease course and treatment response are still limited. Circulating tumor cells (CTCs) are malignant cells that detach from the primary tumor and enter the bloodstream. Their presence has been associated with disease progression and prognosis in several malignancies, including ovarian cancer. However, data on the morphological characteristics, immunophenotype, and clinical relevance of CTCs in high-grade serous ovarian cancer remain limited. The ASTRA study evaluates the number and characteristics of circulating tumor cells in peripheral blood samples obtained from patients with high-grade serous ovarian cancer. The study examines CTC count, presence of CTC clusters and megakaryocytes, and immunophenotypic marker expression, and explores associations between CTC findings and clinical parameters and outcomes. Results from this study may contribute to improved understanding of circulating tumor cells in ovarian cancer and support the development of liquid biopsy approaches for prognostic assessment and disease monitoring.	Cancer	NA	Ralentissement de la progression + Immunomodulation	Slovenia	À vérifier
Assessment of Endocrine and Metabolic Late Effects After Childhood Brain Tumor TreatmentThis prospective, single-group interventional study evaluates endocrine and metabolic late effects in survivors of primary brain tumors treated during childhood. According to the study protocol, participants were prospectively assigned to undergo the Study-Specific Endocrine and Metabolic Late-Effects Assessment. The assessment included anthropometric measurements, repeated blood pressure measurements, clinical endocrine evaluation, fasting laboratory testing, and protocol-defined bone and vascular assessments. The purpose of the study was to identify the frequency and severity of endocrine and metabolic late effects and to evaluate their associations with tumor characteristics, previous cancer treatment, age at diagnosis, and physical functioning.	Cancer	Non applicable	À vérifier	Slovenia	À vérifier

Essais cliniques

2

Molécule	Indication / population	Phase	NCT	Titre	Statut
Assessment of Endocrine and Metabolic Late Effects After Childhood Brain Tumor Treatment	Cancer	Non applicable	NCT07716579	Assessment of Endocrine and Metabolic Late Effects After Childhood Brain Tumor Treatment	COMPLETED
ASTRA Study: Circulating Tumor Cells in Blood of Patients With High-Grade Serous Ovarian Cancer	Cancer	NA	NCT07439328	ASTRA Study: Circulating Tumor Cells in Blood of Patients With High-Grade Serous Ovarian Cancer	COMPLETED

Publications

4

Molécule	Indication / population	Titre	Journal	Date
Assessment of Endocrine and Metabolic Late Effects After Childhood Brain Tumor Treatment		Poor bone health at the end of puberty in childhood cancer survivors.	Pediatric blood & cancer
Assessment of Endocrine and Metabolic Late Effects After Childhood Brain Tumor Treatment		[Endocrine late-effects and bone mineral density after combined treatment of malignant brain tumors in childhood and adolescence].	Problemy endokrinologii
Assessment of Endocrine and Metabolic Late Effects After Childhood Brain Tumor Treatment		Hypothalamic-Pituitary and Other Endocrine Surveillance Among Childhood Cancer Survivors.	Endocrine reviews
ASTRA Study: Circulating Tumor Cells in Blood of Patients With High-Grade Serous Ovarian Cancer		Phenotypic and genotypic characterization of single circulating tumor cells in the follow-up of high-grade serous ovarian cancer.	Molecular oncology